VitalTrace partners with IPREP in 2020

VitalTrace is proud to announce it is one of 9 WA innovators and start ups to have received support from the Western Australian government, under the Future Health Research and Innovation (FHRI) Fund.

The Innovation Seed Fund is intended to bridge the gap in access to early-stage funding for WA start-ups to be more competitive in securing follow-on funding and develop into sustainable businesses, create high-level health sector jobs and enhance the production/manufacturing capacity of WA.

This project will fund the development of a commercialisation ready and clinically compatible product to improve maternal and fetal health outcomes during childbirth.

Medical Research Minister Stephen Dawson said “[VitalTrace has] the potential to change lives, and this funding will help them secure capital and develop into sustainable businesses.”

Read more here

From Prof. Jonathan Morris, VitalTrace - Chief Medical Officer

I had the wonderful opportunity to present VitalTrace’s pre-clinical data in the highly regarded Society for Maternal-Fetal Medicine 2025 Pregnancy Meeting in Denver, Colorado. This is the premier pregnancy meeting in USA. Our abstract was one of the 104 selected for presentation out of more than 2,000 submitted speaking to the significance and magnitude of the accomplishments we have achieved.

SMFM was a great opportunity to connect with obstetricians allowing VitalTrace to build invaluable relationships with leading practitioners and forming alliances to prepare the company for future activity in the United States and beyond. There was very strong interest in DelivAssure from leaders in Boston, Washington, Texas, East Virginia, New York and Philadelphia amongst others.

Some particularly notable feedback:

From Dr Emily Reiff (Brigham and Women’s Hospital, Harvard Medical School),

“I was fascinated by your study of real-time fetal lactate monitoring and think that innovation like this is what is needed for effective intrapartum management.”
‍

From Dr Justin Lappen (Cleveland Clinic),

“The whole team thought that DelivAssure would assist with Class II CTG dilemmas.”

‍

It was reinvigorating to see such strong support for continuous lactate monitoring and reinforces our confidence to launch DelivAssure in the United States.

Our first peer-reviewed journal article has been published in The SMFM Pregnancy Journal — the official open-access journal of the Society for Maternal-Fetal Medicine (SMFM) based in Washington, DC.

In collaboration with The University of Western Australia, our study demonstrates the capability of our technology, DelivAssure, in detecting early signs of fetal lactic acidosis, highlighted by the strong correlation between sensor current and venous blood lactate levels.  

We're proud to contribute to the growing body of evidence aimed at improving outcomes for mothers and babies — DelivAssure has the potential to revolutionise intrapartum care by enabling crucial early detection and management of fetal asphyxia during labor and delivery.

📰 Read the full article here: https://onlinelibrary.wiley.com/doi/10.1002/pmf2.70017

We're incredibly grateful to our collaborators, clinical partners, and the SMFM editorial team for supporting this work.